Open AccessLncRNA DLX6-AS1 regulates osteosarcoma progression via the miR-200a-3p/GPM6P axis
Author(s) -
Tianyi Wu,
Chen Huang,
Rui Wang
Publication year - 2022
Publication title -
stemedicine
Language(s) - English
Resource type - Journals
ISSN - 2705-1188
DOI - 10.37175/stemedicine.v3i1.111
Subject(s) - gene knockdown , cancer research , cell growth , in vivo , microrna , osteosarcoma , downregulation and upregulation , cell culture , cell , transcription factor , microbiology and biotechnology , metastasis , biology , chemistry , gene , cancer , biochemistry , genetics
LncRNA DLX6-AS1 takes part in the progression of various cancers. However, it is not elaborated clearly in osteosarcoma (OS) development. Therefore, we aimed to explore the impacts and specific mechanisms of DLX6-AS1 on the progression of OS. We estimated the pattern of DLX6-AS1 expression in Ost tissues and cells via quantitative reverse transcription polymerase chain reaction. A number of biochemical assays were carried out to assess the effects of DLX6-AS1. Target genes were predicted by bioinformatics methods. Then we used the transfection of si-RNA, miRNA inhibitor, and miRNA mimics to explore the underlying mechanisms and built tumor xenograft models for the in vivo experiments. A higher expression of DLX6-AS1 was found in OS tissues and cell lines, while knockdown of DXL6-AS1 suppressed OS cell metastasis and proliferation in vitro and in vivo. Mechanistically, it was revealed that DXL6-AS1 sponged miR-200a-3p, thus positively regulating the downstream GPM6B. In summary, DLX6-AS1 knockdown would inhibit OS cell migration, cell invasion, and cell proliferation, in which the DXL6-AS1/ miR-200a-3p/ GPM6B axis played a critical role.